HER2-mutant Non-Small Cell Lung Cancer Pipeline Report provides Therapeutic Assessment of the Key 5+ Pipeline Therapies in this Domain

DelveInsight's, "HER2-mutant Non-Small Cell Lung Cancer- Pipeline Insight, 2023" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in HER2-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

For HER2-mutant Non-Small Cell Lung Cancer Emerging drugs, the HER2-mutant Non-Small Cell Lung Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The HER2-mutant Non-Small Cell Lung Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

In the HER2-mutant Non-Small Cell Lung Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, HER2-mutant Non-Small Cell Lung Cancer clinical trials studies, HER2-mutant Non-Small Cell Lung Cancer NDA approvals (if any), and product development activities comprising the technology, HER2-mutant Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Key takeaways from the HER2-mutant Non-Small Cell Lung Cancer Pipeline Report

• Over 5+ HER2-mutant Non-Small Cell Lung Cancer companies are evaluating 5+ HER2-mutant Non-Small Cell Lung Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the HER2-mutant Non-Small Cell Lung Cancer market would significantly increase market revenue.

• The leading HER2-mutant Non-Small Cell Lung Cancer Companies include Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, Spectrum Pharmaceuticals, Inc., and others.

• Promising HER2-mutant Non-Small Cell Lung Cancer Pipeline Therapies include DZD-9008, Enhertu, Pyrotinib, and others.

• The HER2-mutant Non-Small Cell Lung Cancer companies and academics are working to assess challenges and seek opportunities that could influence HER2-mutant Non-Small Cell Lung Cancer R&D. The HER2-mutant Non-Small Cell Lung Cancer pipeline therapies under development are focused on novel approaches to treat/improve HER2-mutant Non-Small Cell Lung Cancer.

Request a sample and discover the recent breakthroughs happening in the HER2-mutant Non-Small Cell Lung Cancer Pipeline landscape, visit here for HER2-mutant Non-Small Cell Lung Cancer Pipeline Outlook Report @ https://www.delveinsight.com/sample-request/her2-mutant-non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

HER2-mutant Non-Small Cell Lung Cancer Overview
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancers. NSCLC is one of the most genomically diverse cancers, making it very difficult to treat. For all NSCLC patients who have the adenocarcinoma subtype, testing for alterations in epidermal growth factor receptor (EGFR), mesenchymal epithelial transition factor (MET), b-raf proto-oncogene (BRAF), anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), ret proto-oncogene (RET) and neurotrophic tyrosine receptor kinase (NTRK) is recommended by the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) guidelines.

HER2-mutant Non-Small Cell Lung Cancer Emerging Drugs Profile

• DZD-9008: Dizal Pharmaceuticals
DZD9008 is a selective, irreversible EGFR inhibitor, which is currently being evaluated for the treatment of both EGFRexon20 insertion mutation-positive NSCLC and HER2-mutated NSCLC. In the open-label, multicenter phase I/II study (NCT03974022), 220 patients with EGFRexon20 insertion mutation-positive or HER2-positive NSCLC were treated with DZD9008 at doses of 50 mg to 400 mg once daily.

• Enhertu: AstraZeneca
Enhertu is a HER2-directed ADC. Designed using Daiichi Sankyo's proprietary DXd ADC technology, Enhertu is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced programme in AstraZeneca's ADC scientific platform. Enhertu consists of a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker. Enhertu (5.4mg/kg) is approved in more than 40 countries for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens based on the results from the DESTINY-Breast01 trial. Enhertu (6.4mg/kg) is approved in several countries for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastro esophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01 trial.

• Pyrotinib: Jiangsu Hengrui Medicine
Pyrotinib is a novel irreversible and selective EGFR/HER2 tyrosine kinase inhibitor developed by Hengrui. In 2018, pyrotinib was approved in China in combination with capecitabine for the treatment of relapsed or metastatic HER2-positive breast cancer. Currently, two Phase III studies are ongoing to evaluate pyrotinib as 1st-line treatment (NCT03863223) and extended adjuvant treatment (NCT03980054), respectively in HER2-positive breast cancer patients. In addition to breast cancer, pyrotinib demonstrated superior clinical benefits in advanced non-small cell lung cancer (NSCLC) with HER2 exon 20 mutation in a Phase II study. A global Phase III study (NCT04447118) is ongoing to investigate pyrotinib in patients with advanced non-squamous NSCLC with HER2 exon 20 mutation who previously failed platinum-based chemotherapy.

For further information, refer to the detailed HER2-mutant Non-Small Cell Lung Cancer Drugs Launch, HER2-mutant Non-Small Cell Lung Cancer Developmental Activities, and HER2-mutant Non-Small Cell Lung Cancer News, click here for HER2-mutant Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis @ https://www.delveinsight.com/sample-request/her2-mutant-non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

HER2-mutant Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for HER2-mutant Non-Small Cell Lung Cancer. The companies which have their HER2-mutant Non-Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. Preregistration include, AstraZeneca.

HER2-mutant Non-Small Cell Lung Cancer Pipeline: Phases
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

HER2-mutant Non-Small Cell Lung Cancer Pipeline: Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

HER2-mutant Non-Small Cell Lung Cancer Pipeline: Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Find out more about the HER2-mutant Non-Small Cell Lung Cancer Pipeline Segmentation, Therapeutics Assessment, HER2-mutant Non-Small Cell Lung Cancer Emerging Drugs, and visit here for HER2-mutant Non-Small Cell Lung Cancer Treatment Landscape @ https://www.delveinsight.com/sample-request/her2-mutant-non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the HER2-mutant Non-Small Cell Lung Cancer Pipeline Report

• Coverage- Global

• HER2-mutant Non-Small Cell Lung Cancer Companies- Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, Spectrum Pharmaceuticals, Inc., and others.

• HER2-mutant Non-Small Cell Lung Cancer Pipeline Therapies- DZD-9008, Enhertu, Pyrotinib, and others.

• HER2-mutant Non-Small Cell Lung Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for HER2-mutant Non-Small Cell Lung Cancer Pipeline Companies and Therapies, click here for HER2-mutant Non-Small Cell Lung Cancer Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/her2-mutant-non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. HER2-mutant Non-Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HER2-mutant Non-Small Cell Lung Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Preregistration)
8. Enhertu: AstraZeneca
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. DZD-9008: Dizal Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name : Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. HER2-mutant Non-Small Cell Lung Cancer Key Companies
21. HER2-mutant Non-Small Cell Lung Cancer Key Products
22. HER2-mutant Non-Small Cell Lung Cancer- Unmet Needs
23. HER2-mutant Non-Small Cell Lung Cancer- Market Drivers and Barriers
24. HER2-mutant Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
25. HER2-mutant Non-Small Cell Lung Cancer Analyst Views
26. HER2-mutant Non-Small Cell Lung Cancer Key Companies
27. Appendix

Got Queries? Find out the related information on HER2-mutant Non-Small Cell Lung Cancer Mergers and acquisitions, HER2-mutant Non-Small Cell Lung Cancer Licensing Activities, just visit here for HER2-mutant Non-Small Cell Lung Cancer Recent Trends, and Future Perspectives @ https://www.delveinsight.com/sample-request/her2-mutant-non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Healthcare Partner Identification Services @ https://www.delveinsight.com/consulting/partner-identification-services

Medical Marijuana Market @ https://www.delveinsight.com/report-store/medical-marijuana-market-insight

Oncolytic Virus Cancer Therapy Pipeline @ https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021

Overactive Bladder Syndrome Market @ https://www.delveinsight.com/report-store/overactive-bladder-market

Pediatric Growth Hormone Deficiency PGHD Market @ https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market

Percutaneous Arterial Closure Device Market @ https://www.delveinsight.com/report-store/percutaneous-arterial-closure-device-market

Ranibizumab Biosimilars Insight @ https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight

Schistosomiasis Market @ https://www.delveinsight.com/report-store/schistosomiasis-market

Stem Cell Market @ https://www.delveinsight.com/report-store/stem-cell-market

Superficial Punctate Keratitis Market @ https://www.delveinsight.com/report-store/superficial-punctate-keratitis-market

Technical Due Diligence @ https://www.delveinsight.com/consulting/due-diligence-services

Transient Ischemic Attack Market @ https://www.delveinsight.com/report-store/transient-ischemic-attack-market

Wilms Tumor Market @ https://www.delveinsight.com/report-store/wilms-tumor-market

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash Bhardwaj

info@delveinsight.com

This release was published on openPR.